Table 1.
Percentage of drug-resistant community-acquired urinary tract E. coli isolates collected during five surveillance network studies
| Antimicrobial | Country (network), year (no. of isolates) | ||||
|---|---|---|---|---|---|
| Guatemala [40] | Ecuador (REDNARBEC) [25] | Chilean network [41] | Argentina, Brazil, Chile, Mexico, Venezuela (SENTRY) [19] | ||
| 2005–2010 (n = 1184) | 1999 (n = 1907) | 2007 (n = 6447) | 2009 (n = 36 949) | 2003 (n = 403) | |
| Ampicillin | 57 | 72 | 53·6 n.s. | 53·6 | |
| Ampicillin/sulbactam | 29·3 | 19 | 27 | 23·3 | |
| Amoxicillin/clavulanate | 1·2 | ||||
| Piperacillin/tazobactam | 2·9 | 6·4 n.s. | 0·2 | ||
| C1G | 25*, 8† | 29*, 9† | 31·8* n.s. | ||
| C2G | 3‡ | 9‡ | 2·2‡ | ||
| C3G | 2·5§, 10·8|| | 1¶ | 3¶ | 5·6|| | 1·5§, 1·2¶ |
| C4G | 8·3# | 1·0# | |||
| Cefoxitin | 1·7 | ||||
| Gentamicin | 21·9 | 3 | 18 | 6·9 n.s. | 8·4 |
| Amikacin | 1·4 | 0·5 | 0·9 | 7·5 n.s. | 0 |
| Ciprofloxacin | 46·3 | 18 | 41 | 19·6 n.s. | 21·6 |
| Trimethoprim/sulfamethoxazole | 58·6 | 50 | 57 | 29·6 n.s. | 40·4 |
| Nitrofurantoin | 2·5 | 4 | 7 | 4 n.s. | 6·9 |
| Ertapenem | 0 n.s. | ||||
| Imipenem | 0 | 0 n.s. | 0 | ||
| Meropenem | 0 | 0 n.s. | |||
| Fosfomycin | 1 | 2 | |||
REDNARBEC, Red Nacional de Resistencia Bacteriana de Ecuador; C1G, First-generation cephalosporins; C2G, second-generation cephalosporins; C3G, third-generation cephalosporins; C4G, fourth-generation cephalosporins; n.s., non-susceptible.
*
Cefalotin; † cefazolin; ‡ cefuroxime; § ceftazidime; || cefotaxime; ¶ ceftriaxone; # cefepime.